|
| | Issue Date | Title | Contributor(s) | Type | Cat. |
| 101 | 2018 | Durable suppression of MRI disease activity and slowing of brain volume loss in alemtuzumab-treated patients with active RRMS: 7-year follow-up of CARE-MS I (TOPAZ Study) | Schippling, S.; Arnold, D.; Barnett, M.; Comi, G.; Laganke, C.; Rovira, A.; Traboulsee, A.; Melanson, M.; Daizadeh, N.; Nakamura, K.; VAN WIJMEERSCH, Bart; Pelletier, D. | Journal Contribution | M |
| 102 | 2018 | Lack of apparent association between lymphocyte repopulation kinetics and autoimmune events in alemtuzumab-treated patients with relapsing-remitting Multiple Sclerosis through 6 years: CARE-MS extension | Wiendl, H.; Carraro, M.; Comi, G.; Izquierdo, G.; Kim, H. J.; Sharrack, B.; Tornatore, C.; Daizadeh, N.; Melanson, M.; JACOBS, Andre; VAN WIJMEERSCH, Bart | Journal Contribution | M |
| 103 | 2018 | Alemtuzumab provides durable clinical efficacy in patients with active rrms in the absence of continuous treatment: 7-Year follow-up of CARE-MS I (TOPAZ Study) | VAN WIJMEERSCH, Bart; Vermersch, P.; Boyko, A.; de Seze, J.; Hartung, H. -P.; Havrdova, E. Kubala; Inshasi, J. Said; McCombe, P.; Montalban, X.; Pozzili, C.; Melanson, M.; Daizadeh, N.; Rodriguez, C.; Selmaj, K. | Journal Contribution | M |
| 104 | 2018 | Long-term Improvement in Clinical Outcomes in Alemtuzumab-Treated RRMS Patients Who Relapsed Between Courses 1 and 2 (CARE-MS I) | Broadley, S.; Wiendl, Heinz; Fernandez, O.; Freedman, M. S.; Izquierdo, G.; Lycke, J.; Pozzilli, C.; Sharrack, B.; Singer, B. A.; Steingo, B.; Vermersch, P.; Wray, S.; VAN WIJMEERSCH, Bart; Ziemssen, T.; Margolin, D. H.; Thangavelu, K.; Boster, A. | Journal Contribution | M |
| 105 | 2018 | No correlation between lymphocyte repopulation kinetics and MS disease activity following alemtuzumab treatment in patients with relapsing-remitting multiple sclerosis | Wiendl, H.; Brandes, D.; Carraro, M.; Comi, G.; Mao-Draayer, Y.; Izquierdo, G.; Kim, H. -J.; Meuth, S.; Pardo, G.; Sharrack, B.; Tornatore, C.; Ziemssen, T.; JACOBS, Andre; Chung, L.; Daizadeh, N.; VAN WIJMEERSCH, Bart | Journal Contribution | M |
| 106 | 2018 | No correlation between lymphocyte pharmacodynamics and autoimmune adverse events following alemtuzumab treatment in patients with relapsing-remitting multiple sclerosis | Wiendl, H.; Brandes, D.; Carraro, M.; Comi, G.; Mao-Draayer, Y.; Izquierdo, G.; Kim, H. -J.; Meuth, S.; Pardo, G.; Sharrack, B.; Tornatore, C.; Ziemssen, T.; Jacobs, Alessia; Chung, L.; Daizadeh, N.; VAN WIJMEERSCH, Bart | Journal Contribution | M |
| 107 | 2018 | Alemtuzumab outcomes over 6 years in RRMS patients who switched from SC IFNB-1a: follow-up of CARE-MS I patients (TOPAZ study) | VAN WIJMEERSCH, Bart; Barone, D.; Broadley, S.; Dive, D.; Hupperts, R. M. M.; Lycke, J.; Massacesi, L.; Montalban, X.; Naismith, R. T.; Pandey, K.; Schippling, S.; Vermersch, P.; Chung, L.; Daizadeh, N.; Rodriguez, C. E.; Nakamura, K.; Wiendl, H. | Journal Contribution | M |
| 108 | 2018 | DURABLE CLINICAL EFFICACY OF ALEMTUZUMAB IN PATIENTS WITH ACTIVE RRMS IN THE ABSENCE OF CONTINUOUS TREATMENT: 7-YEAR FOLLOW-UP OF CARE-MS I PATIENTS (TOPAZ STUDY) | McCombe, Pamela; Boyko, Alexey N.; DeSeze, Jerome; Hartung, Hans-Peter; Havrdova, Eva; Inshasi, Jihad Said; Montalban, Xavier; Pozzilli, Carlo; Selmaj, Krzysztof W.; Vermersch, Patrick; Melanson, Maria; Daizadeh, Nadia; Rodriguez, Claudio E.; VAN WIJMEERSCH, Bart | Journal Contribution | M |
| 109 | 2018 | A Belgian consensus protocol for autologous hematopoietic stem cell transplantation in multiple sclerosis | Laureys, Guy; Willekens, Barbara; Vanopdenbosch, Ludo; Deryck, Olivier; Selleslag, Dominik; D'Haeseleer, Miguel; De Becker, Ann; Dubois, Benedicte; Dierickx, Daan; Perrotta, Gaetano; De Wilde, Virginie; van Pesch, Vincent; Straetmans, Nicole; Dive, Dominique; Beguin, Yves; VAN WIJMEERSCH, Bart; Theunissen, Koen; Kerre, Tessa; Van de Velde, Ann | Journal Contribution | A1 |
| 110 | 2018 | Dimethyl fumarate induces a persistent change in the composition of the innate and adaptive immune system in multiple sclerosis patients | MONTES DIAZ, Gwendoline; FRAUSSEN, Judith; VAN WIJMEERSCH, Bart; Hupperts, R.; SOMERS, Veerle | Journal Contribution | A1 |
| 111 | 2018 | Walking endurance and perceived symptom severity after a single maximal exercise test in persons with mild disability because of multiple sclerosis. | MOUMDJIAN, Lousin; GERVASONI, Elisa; VAN HALEWYCK, Florian; OP 'T EIJNDE, Bert; WENS, Inez; VAN GEEL, Fanny; VAN WIJMEERSCH, Bart; FEYS, Peter; VAN ASCH, Paul | Journal Contribution | A1 |
| 112 | 2018 | Improving fatigue in multiple sclerosis by smartphone-supported energy management: The MS TeleCoach feasibility study | D'hooghe, Marie; Van Gassen, Geert; Kos, Daphne; Bouquiaux, Olivier; Cambron, Melissa; Decoo, Danny; Lysandropoulos, Andreas; VAN WIJMEERSCH, Bart; Willekens, Barbara; Penner, Iris-Katharina; Nagels, Guy | Journal Contribution | A1 |
| 113 | 2018 | Twelve Weeks of Medium-Intensity Exercise Therapy Affects the Lipoprotein Profile of Multiple Sclerosis Patients. | JORISSEN, Winde; VANMIERLO, Tim; WENS, Inez; SOMERS, Veerle; VAN WIJMEERSCH, Bart; BOGIE, Jeroen; Remaley, Alan; OP 'T EIJNDE, Bert; HENDRIKS, Jerome | Journal Contribution | A1 |
| 114 | 2018 | Multidisciplinary data infrastructures in multiple sclerosis: Why they are needed and can be done! | PEETERS, Liesbet; van Munster, Caspar E.; VAN WIJMEERSCH, Bart; BRUYNDONCKX, Robin; LAMERS, Ilse; HELLINGS, Niels; POPESCU, Veronica; Thalheim, Christoph; FEYS, Peter | Journal Contribution | A1 |
| 115 | 2017 | Does including the full CVLT-II and BVMT-R improve BICAMS? Evidence from a Belgian (Dutch) validation study. | Costers, Lars; Gielen, Jeroen; Eelen, Piet L.; Van Schependom, Jeroen; Laton, Jorne; Van Remoortel, Ann; VANZEIR, Ellen; VAN WIJMEERSCH, Bart; Seeldrayers, Pierrette; Haelewyck, Marie-Claire; D'Haeseleer, Miguel; D'hooghe, Marie-Beatrice; Langdon, Dawn; Nagels, Guy | Journal Contribution | M |
| 116 | 2017 | Comparative clinical efficacy of alemtuzumab and ocrelizumab in patients with relapsing-remitting multiple sclerosis: Number needed to treat analyses | Comi, G.; Boster, A.; Alroughani, R.; Berkovich, R.; Izquierdo, G.; Kantor, D.; Laganke, C.; Limmroth, V.; Macdonell, R.; Moreau, T.; Sharrack, B.; Wiendl, H.; VAN WIJMEERSCH, Bart; Margolin, D. H.; Thangavelu, K.; Melanson, M.; Freedman, M. S. | Journal Contribution | M |
| 117 | 2017 | Teri-DYNAMIC: Exploring the impact of teriflunomide on immune cell population size, receptor repertoire, and function in patients with RRMS | Wiendl, Heinz; Gross, Catharina C.; Eschborn, Melanie; Weisser, Linda; Posevitz-Fejfar, Anita; Schulte-Mecklenbeck, Andreas; VAN WIJMEERSCH, Bart; Hupperts, Raymond; Brette, Sandrine; Turner, Timothy J.; Bar-Or, Amit; Klotz, Luisa | Journal Contribution | M |
| 118 | 2017 | Cytomegalovirus infection exacerbates autoimmune mediated neuroinflammation | VANHEUSDEN, Marjan; BROUX, Bieke; Welten, Suzanne P. M.; PEETERS, Liesbet; Panagioti, Eleni; VAN WIJMEERSCH, Bart; SOMERS, Veerle; STINISSEN, Piet; Arens, Ramon; HELLINGS, Niels | Journal Contribution | A1 |
| 119 | 2017 | Cytotoxic CD4+T Cells Drive Multiple Sclerosis Progression | PEETERS, Liesbet; VANHEUSDEN, Marjan; SOMERS, Veerle; VAN WIJMEERSCH, Bart; STINISSEN, Piet; BROUX, Bieke; HELLINGS, Niels | Journal Contribution | A1 |
| 120 | 2017 | Does including the full CVLT-II and BVMT-R improve BICAMS? Evidence from a Belgian (Dutch) validation study | Costers, Lars; Gielen, Jeroen; Eelen, Piet L.; van Schependom, Jeroen; Laton, Jorne; Van Remoortel, Ann; VANZEIR, Ellen; VAN WIJMEERSCH, Bart; Seeldrayers, Pierrette; Haelewyck, Marie-Claire; D'Haeseleer, Miguel; D'hooghe, Marie-Beatrice; Langdon, Dawn; Nagels, Guy | Journal Contribution | A1 |
Loading...
5
0
5
0
false